SinoMab BioScience (FRA:4VF) 12-1 Month Momentum %: N/A% (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4VF SinoMab BioScience Ltd FRA:4VF
19 GF Score
Price €0.12
! 2 Warning Signs
View Full Analysis

What is SinoMab BioScience 12-1 Month Momentum %?

SinoMab BioScience FRA:4VF 19 12-1 Month Momentum % is N/A% as of Sep. 10, 2026. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,356 Biotechnology companies, SinoMab BioScience ranks worse than 69.1% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-10), SinoMab BioScience's 12-1 Month Momentum % is N/A%.

The industry rank for SinoMab BioScience's 12-1 Month Momentum % or its related term are showing as below:

FRA:4VF's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -20.345
* Ranked among companies with meaningful 12-1 Month Momentum % only.

SinoMab BioScience  (FRA:4VF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

SinoMab BioScience 12-1 Month Momentum % Related Terms

FRA:4VF
19GF Score
SinoMab BioScience Ltd FRA:4VF
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SinoMab BioScience  (FRA:4VF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
SinoMab BioScience (FRA:4VF) has a 12-1 Month Momentum % of N/A% as of Sep. 10, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #937 out of 1356 companies in the Biotechnology industry, placing it in the top 69.1%.
Is SinoMab BioScience's 12-1 Month Momentum % too high?
SinoMab BioScience's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, SinoMab BioScience ranks #937 out of 1356 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #937 out of 1356 companies for 12-1 Month Momentum %. This places SinoMab BioScience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on SinoMab BioScience and its competitors. SinoMab BioScience's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current 12-1 Month Momentum % is N/A% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SinoMab BioScience Business Description

Other Exchanges 03681:Hong Kong
Address No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score

Get the complete analysis for FRA:4VF

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price